CN112424187B - 抑制jak的化合物的昔萘酸盐 - Google Patents
抑制jak的化合物的昔萘酸盐 Download PDFInfo
- Publication number
- CN112424187B CN112424187B CN201980047093.4A CN201980047093A CN112424187B CN 112424187 B CN112424187 B CN 112424187B CN 201980047093 A CN201980047093 A CN 201980047093A CN 112424187 B CN112424187 B CN 112424187B
- Authority
- CN
- China
- Prior art keywords
- fluoro
- formula
- xinafoate
- added
- mmol
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
- C07C51/41—Preparation of salts of carboxylic acids
- C07C51/412—Preparation of salts of carboxylic acids by conversion of the acids, their salts, esters or anhydrides with the same carboxylic acid part
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C59/235—Saturated compounds containing more than one carboxyl group
- C07C59/245—Saturated compounds containing more than one carboxyl group containing hydroxy or O-metal groups
- C07C59/255—Tartaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C65/00—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
- C07C65/01—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups
- C07C65/105—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic
- C07C65/11—Compounds having carboxyl groups bound to carbon atoms of six—membered aromatic rings and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups containing hydroxy or O-metal groups polycyclic with carboxyl groups on a condensed ring system containing two rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
- C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
- C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
- C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Pulmonology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202410624343.9A CN118580223A (zh) | 2018-07-18 | 2019-07-17 | 抑制jak的化合物的昔萘酸盐 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862699955P | 2018-07-18 | 2018-07-18 | |
| US62/699955 | 2018-07-18 | ||
| US201962866013P | 2019-06-25 | 2019-06-25 | |
| US62/866013 | 2019-06-25 | ||
| PCT/EP2019/069252 WO2020016302A1 (en) | 2018-07-18 | 2019-07-17 | A xinafoate salt of a jak inhibiting compound |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410624343.9A Division CN118580223A (zh) | 2018-07-18 | 2019-07-17 | 抑制jak的化合物的昔萘酸盐 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN112424187A CN112424187A (zh) | 2021-02-26 |
| CN112424187B true CN112424187B (zh) | 2024-06-21 |
Family
ID=67396927
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201980047093.4A Active CN112424187B (zh) | 2018-07-18 | 2019-07-17 | 抑制jak的化合物的昔萘酸盐 |
| CN202410624343.9A Pending CN118580223A (zh) | 2018-07-18 | 2019-07-17 | 抑制jak的化合物的昔萘酸盐 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202410624343.9A Pending CN118580223A (zh) | 2018-07-18 | 2019-07-17 | 抑制jak的化合物的昔萘酸盐 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US11149029B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3823964A1 (cg-RX-API-DMAC7.html) |
| JP (2) | JP7422732B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102849420B1 (cg-RX-API-DMAC7.html) |
| CN (2) | CN112424187B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2019304014B2 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112021000467A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3105585A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL280025B2 (cg-RX-API-DMAC7.html) |
| MA (1) | MA53162A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2021000611A (cg-RX-API-DMAC7.html) |
| MY (1) | MY209356A (cg-RX-API-DMAC7.html) |
| SG (1) | SG11202100240RA (cg-RX-API-DMAC7.html) |
| WO (1) | WO2020016302A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN115260128B (zh) * | 2022-09-21 | 2022-12-09 | 苏州凯瑞医药科技有限公司 | 一种新型jak抑制剂关键中间体的制备方法 |
| GB202316063D0 (en) | 2023-10-20 | 2023-12-06 | Astrazeneca Ab | Dosing regime |
| GB202403369D0 (en) | 2024-03-08 | 2024-04-24 | Astrazeneca Ab | Process and intermediates for the production of a jak1 inhibitor |
| WO2026132265A1 (en) | 2024-12-19 | 2026-06-25 | Astrazeneca Ab | Dry powder inhaler |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105658646A (zh) * | 2013-11-01 | 2016-06-08 | 诺华股份有限公司 | 作为激酶抑制剂的氨基杂芳基苯甲酰胺 |
| CN106831538A (zh) * | 2017-01-22 | 2017-06-13 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
| WO2018134213A1 (en) * | 2017-01-17 | 2018-07-26 | Astrazeneca Ab | Jak1 selective inhibitors |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2452965T3 (es) * | 2007-09-05 | 2014-04-03 | Rigel Pharmaceuticals, Inc. | Sal de xinafoato de N4-[(2,2-difluoro-4H-benzo[1,4]oxazin-3-ona)-6-il]-5-fluoro-N2-[3-(metilaminocarbonilmetilenoxi)fenil]-2,4-pirimidindiamina |
| RU2013114352A (ru) * | 2010-09-15 | 2014-10-20 | Ф. Хоффманн-Ля Рош Аг | Азабензотиазолы, композиции и способы применения |
| PL3189045T3 (pl) * | 2014-08-11 | 2022-04-04 | Sun Pharmaceutical Industries Limited | Nowe sole nilotynibu i jego polimorfy |
| KR102774784B1 (ko) * | 2015-09-25 | 2025-02-27 | 디잘 (지앙수) 파마슈티칼 씨오., 리미티드 | Jak를 억제하기 위한 화합물 및 방법 |
-
2019
- 2019-07-17 US US16/513,781 patent/US11149029B2/en active Active
- 2019-07-17 EP EP19742558.0A patent/EP3823964A1/en active Pending
- 2019-07-17 CA CA3105585A patent/CA3105585A1/en active Pending
- 2019-07-17 AU AU2019304014A patent/AU2019304014B2/en active Active
- 2019-07-17 KR KR1020217001860A patent/KR102849420B1/ko active Active
- 2019-07-17 JP JP2021502626A patent/JP7422732B2/ja active Active
- 2019-07-17 CN CN201980047093.4A patent/CN112424187B/zh active Active
- 2019-07-17 BR BR112021000467-0A patent/BR112021000467A2/pt unknown
- 2019-07-17 WO PCT/EP2019/069252 patent/WO2020016302A1/en not_active Ceased
- 2019-07-17 MA MA053162A patent/MA53162A/fr unknown
- 2019-07-17 IL IL280025A patent/IL280025B2/en unknown
- 2019-07-17 MY MYPI2021000231A patent/MY209356A/en unknown
- 2019-07-17 SG SG11202100240RA patent/SG11202100240RA/en unknown
- 2019-07-17 CN CN202410624343.9A patent/CN118580223A/zh active Pending
- 2019-07-17 MX MX2021000611A patent/MX2021000611A/es unknown
-
2023
- 2023-10-02 JP JP2023171327A patent/JP7644190B2/ja active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN105658646A (zh) * | 2013-11-01 | 2016-06-08 | 诺华股份有限公司 | 作为激酶抑制剂的氨基杂芳基苯甲酰胺 |
| WO2018134213A1 (en) * | 2017-01-17 | 2018-07-26 | Astrazeneca Ab | Jak1 selective inhibitors |
| CN106831538A (zh) * | 2017-01-22 | 2017-06-13 | 苏州楚凯药业有限公司 | 托法替尼中间体的制备方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| IL280025A (en) | 2021-03-01 |
| WO2020016302A1 (en) | 2020-01-23 |
| AU2019304014B2 (en) | 2022-08-18 |
| JP2024001109A (ja) | 2024-01-09 |
| KR20210033474A (ko) | 2021-03-26 |
| IL280025B1 (en) | 2024-10-01 |
| AU2019304014A1 (en) | 2021-03-04 |
| EP3823964A1 (en) | 2021-05-26 |
| JP7422732B2 (ja) | 2024-01-26 |
| JP2021530526A (ja) | 2021-11-11 |
| CA3105585A1 (en) | 2020-01-23 |
| CN112424187A (zh) | 2021-02-26 |
| MA53162A (fr) | 2021-05-26 |
| CN118580223A (zh) | 2024-09-03 |
| JP7644190B2 (ja) | 2025-03-11 |
| MX2021000611A (es) | 2021-04-13 |
| US11149029B2 (en) | 2021-10-19 |
| WO2020016302A8 (en) | 2020-11-12 |
| US20200062737A1 (en) | 2020-02-27 |
| KR102849420B1 (ko) | 2025-08-25 |
| MY209356A (en) | 2025-07-03 |
| BR112021000467A2 (pt) | 2021-04-06 |
| SG11202100240RA (en) | 2021-02-25 |
| IL280025B2 (en) | 2025-02-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113563323B (zh) | 一类苯并噻唑基联芳基类化合物、制备方法和用途 | |
| US9868739B2 (en) | Salt(s) of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7H-pyrrolo[2,3-d]pyrimidine-6-carboxylic acid dimethylamide and processes of making thereof | |
| JP7644190B2 (ja) | Jak阻害化合物のキシナホ酸塩 | |
| JP7105781B2 (ja) | ベンズイミダゾール誘導体、調製方法およびそれらの使用 | |
| US9879008B2 (en) | 2,3,4,6-tetra-substituted benzene-1,5-diamine derivatives, preparation method therefor and medicinal use thereof | |
| US11629153B2 (en) | Forms and compositions of a MK2 inhibitor | |
| JP7797486B2 (ja) | 新規なrho関連タンパク質キナーゼ阻害剤の調製方法およびその調製方法における中間体 | |
| US20250281492A1 (en) | New crystalline forms of salt of 7-cyclopentyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-7h-pyrrolo[2,3-d]pyrimidine -6-carboxylic acid dimethylamide | |
| KR20160116033A (ko) | 2,4-이치환 페닐-1,5-디아민 유도체, 이의 응용, 및 이로 제조한 약물 조성물 | |
| TW202112768A (zh) | 二取代吡唑化合物 | |
| CN113372351A (zh) | 一类jak激酶抑制剂及其制备和应用 | |
| TWI773987B (zh) | 二胺基嘧啶類化合物或其水合物的固體形式及其製備方法和用途 | |
| US20250282761A1 (en) | Salt and crystal forms of an epidermal growth factor receptor inhibitor | |
| EA044028B1 (ru) | Ксинафоатная соль соединения, ингибирующего jak | |
| CN119490507A (zh) | 一种新型激酶抑制剂 | |
| TW202320757A (zh) | Rho相關蛋白激酶抑制劑或其溶劑合物的固體形式及其製備方法和用途 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |